ALZHEIMER'S DISEASE NEUROIMAGING NETWORK (ADNI)

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项非随机自然史非治疗研究，将在美国和加拿大的约50个研究中心招募共计800例受试者，包括200例正常对照、400例MCI患者和200例轻度AD受试者。 ADNI的主要目标是： 1.制定改进的方法， 纵向、多部位MRI采集标准， 轻度阿尔茨海默病（AD）患者的PET数据 认知障碍（MCI）和老年对照。 2.获取一个可普遍访问的数据存储库， 描述了大脑结构的纵向变化， 新陈代谢.同时，获得临床认知和 用于验证成像替代物的生物标志物数据。 3.制定方法，提供最大的力量， 在涉及这些的试验中确定治疗效果 患者 4.基于临床和临床试验， 统计分析中概述的生物标志物数据 科.

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a non-randomized natural history non-treatment study in which a total of 800 subjects including 200 normal controls, 400 individuals with MCI, and 200 subjects with mild AD will be recruited at approximately 50 sites in the United States and Canada. The major goals of the ADNI are to: 1. Develop improved methods which will lead to uniform standards for acquiring longitudinal, multi-site MRI and PET data on patients with Alzheimer s disease (AD), mild cognitive impairment (MCI), and elderly controls. 2. Acquire a generally accessible data repository which describes longitudinal changes in brain structure and metabolism. In parallel, acquire clinical cognitive and biomarker data for validation of imaging surrogates. 3. Develop methods which will provide maximum power to determine treatment effects in trials involving these patients. 4. Test a series of hypotheses based on the clinical and biomarker data as outlined in the statistical analysis section.